Wensheng Deng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wensheng Deng has a total of 105 co-authors. Here are the top co-authors by number of shared publications:
Juan Wang
School of Life Science and Health, Wuhan University of Science and Technology, Wuhan, China; School of Materials and Metallurgy, Wuhan University of Science and Technology, Wuhan, China
18 shared publicationsCheng Zhang
College of Life Science, Xuzhou Medical University, Xuzhou, 221004, China
16 shared publicationsXiaoye Song
School of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430065, China
13 shared publicationsShasha Zhao
School of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430065, China
12 shared publications- Shasha Zhao
School of Life Science and Health, Wuhan University of Science and Technology, Wuhan, China
11 shared publications Deen Yu
School of Life Science and Health, Wuhan University of Science and Technology, Wuhan, 430065, China
8 shared publications
Latest Publications
- 21 July 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 831, 154300
Filamin A inhibits neural stem cell self-renew by downregulating rDNA transcription
- 21 July 2026
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 831, 154300
Filamin A inhibits neural stem cell self-renew by downregulating rDNA transcription
- Open Access
- 9 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Early growth response 1 promotes RNA polymerase I-directed transcription and cancer growth by activating RRN3 expression
Early growth response 1 (EGR1) was identified as a positive regulator in Pol II- and Pol Ⅲ-directed transcription. Whether EGR1 modulates Pol Ⅰ-directed transcription remains unknown. Here, we report that EGR1 is present in the nucleoli of several cancer cell lines. EGR1 positively regulates the synthesis of Pol Ⅰ products and the proliferation of HeLa, HePG2, and AGS cells both in vitro and in vivo. EGR1 silencing increased R-loop formation and lncRNA PAPAS expression, which inversely correlated with Pol Ⅰ product levels. Mechanistically, EGR1 enhances the recruitment of Pol I transcription machinery factors to the rDNA promoter through interactions with these factors. The EGR1 DNA-binding domain mediates the interaction between EGR1 and Pol I machinery components. EGR1 activates RRN3 gene transcription by binding to the RRN3 gene promoter. Thus, EGR1 promotes Pol Ⅰ-directed transcription and cancer cell growth by both interacting with Pol I machinery factors and controlling RRN3 expression.
- 9 January 2026
- Published by Springer Nature in Communications Biology
- Vol. 9 (1)
Open AccessEarly growth response 1 promotes RNA polymerase I-directed transcription and cancer growth by activating RRN3 expression
Early growth response 1 (EGR1) was identified as a positive regulator in Pol II- and Pol Ⅲ-directed transcription. Whether EGR1 modulates Pol Ⅰ-directed transcription remains unknown. Here, we report that EGR1 is present in the nucleoli of several cancer cell lines. EGR1 positively regulates the synthesis of Pol Ⅰ products and the proliferation of HeLa, HePG2, and AGS cells both in vitro and in vivo. EGR1 silencing increased R-loop formation and lncRNA PAPAS expression, which inversely correlated with Pol Ⅰ product levels. Mechanistically, EGR1 enhances the recruitment of Pol I transcription machinery factors to the rDNA promoter through interactions with these factors. The EGR1 DNA-binding domain mediates the interaction between EGR1 and Pol I machinery components. EGR1 activates RRN3 gene transcription by binding to the RRN3 gene promoter. Thus, EGR1 promotes Pol Ⅰ-directed transcription and cancer cell growth by both interacting with Pol I machinery factors and controlling RRN3 expression.
- Open Access
- 24 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7169
The Crucial Role of Epigenetic Modifications in Wharton’s Jelly Stem Cells
Wharton’s jelly mesenchymal stem cells (WJ-SCs) are a promising source for regenerative medicine due to their multipotency, low immunogenicity, and ethical acceptability. Epigenetic regulation plays a crucial role in modulating their proliferation, differentiation, and therapeutic potential. Key mechanisms, including DNA methylation, histone modifications, and non-coding RNAs (e.g., miRNAs and lncRNAs), influence WJ-SC behavior by dynamically altering gene expression without changing the DNA sequence. DNA methylation often silences genes involved in differentiation, while histone acetylation/methylation can activate or repress lineage-specific pathways. Non-coding RNAs further fine-tune these processes by post-transcriptional regulation. Understanding these mechanisms could optimize WJ-SC-based therapies for tissue repair and immune modulation. This review summarizes current insights into epigenetic regulation in WJ-SCs and its implications for regenerative applications.
- 24 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (15) , 7169
Open AccessThe Crucial Role of Epigenetic Modifications in Wharton’s Jelly Stem Cells
Wharton’s jelly mesenchymal stem cells (WJ-SCs) are a promising source for regenerative medicine due to their multipotency, low immunogenicity, and ethical acceptability. Epigenetic regulation plays a crucial role in modulating their proliferation, differentiation, and therapeutic potential. Key mechanisms, including DNA methylation, histone modifications, and non-coding RNAs (e.g., miRNAs and lncRNAs), influence WJ-SC behavior by dynamically altering gene expression without changing the DNA sequence. DNA methylation often silences genes involved in differentiation, while histone acetylation/methylation can activate or repress lineage-specific pathways. Non-coding RNAs further fine-tune these processes by post-transcriptional regulation. Understanding these mechanisms could optimize WJ-SC-based therapies for tissue repair and immune modulation. This review summarizes current insights into epigenetic regulation in WJ-SCs and its implications for regenerative applications.
- 10 February 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1872 (3) , 119914
Filamin A suppresses the expression of ribosomal protein genes by controlling the activity of an EGR1-Sp1-GCN5/PCAF pathway in human cells
- 10 February 2025
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
- Vol. 1872 (3) , 119914
Filamin A suppresses the expression of ribosomal protein genes by controlling the activity of an EGR1-Sp1-GCN5/PCAF pathway in human cells
- Open Access
- 25 September 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1128244
PLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma
Background: Lower-grade glioma (LGG) is a primary intracranial tumor that carry a high risk of malignant transformation and limited therapeutic options. Emerging evidence indicates that the tumor microenvironment (TME) is a superior predictor for tumor progression and therapy response. PLEKHA4 has been demonstrated to be a biomarker for LGG that correlate with immune infiltration. However, the fundamental mechanism by which PLEKHA4 contributes to LGG is still poorly understood.Methods: Multiple bioinformatic tools, including Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA2), Shiny Methylation Analysis Resource Tool (SMART), etc., were incorporated to analyze the PLEKHA4. ESTIMATE, ssGSEA, CIBERSORT, TIDE and CellMiner algorithms were employed to determine the association of PLEKHA4 with TME, immunotherapy response and drug sensitivities. Immunohistochemistry (IHC)-based tissue microarrays and M2 macrophage infiltration assay were conducted to verify their associations.Results: PLEKHA4 expression was found to be dramatically upregulated and strongly associated with unfavorable overall survival (OS) and disease-specific survival (DSS) in LGG patients, as well as their poor clinicopathological characteristics. Cox regression analysis identified that PLEKHA4 was an independent prognostic factor. Methylation analysis revealed that DNA methylation correlates with PLEKHA4 expression and indicates a better outcome in LGG. Moreover, PLEKHA4 was remarkably correlated with immune responses and TME remodeling, as evidenced by its positive correlation with particular immune marker subsets and the putative infiltration of immune cells. Surprisingly, the proportion of M2 macrophages in TME was strikingly higher than others, inferring that PLEKHA4 may regulate the infiltration and polarization of M2 macrophages. Evidence provided by IHC-based tissue microarrays and M2 macrophage infiltration assay further validated our findings. Moreover, PLEKHA4 expression was found to be significantly correlated with chemokines, interleukins, and their receptors, further supporting the critical role of PLEKHA4 in reshaping the TME. Additionally, we found that PLEKHA4 expression was closely associated with drug sensitivities and immunotherapy responses, indicating that PLEKHA4 expression also had potential clinical significance in guiding immunotherapy and chemotherapy in LGG.Conclusion: PLEKHA4 plays a pivotal role in reshaping the TME of LGG patients, and may serve as a potential predictor for LGG prognosis and therapy.
- 25 September 2023
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 14, 1128244
Open AccessPLEKHA4 is a novel prognostic biomarker that reshapes the tumor microenvironment in lower-grade glioma
Background: Lower-grade glioma (LGG) is a primary intracranial tumor that carry a high risk of malignant transformation and limited therapeutic options. Emerging evidence indicates that the tumor microenvironment (TME) is a superior predictor for tumor progression and therapy response. PLEKHA4 has been demonstrated to be a biomarker for LGG that correlate with immune infiltration. However, the fundamental mechanism by which PLEKHA4 contributes to LGG is still poorly understood.Methods: Multiple bioinformatic tools, including Tumor Immune Estimation Resource (TIMER), Gene Expression Profiling Interactive Analysis (GEPIA2), Shiny Methylation Analysis Resource Tool (SMART), etc., were incorporated to analyze the PLEKHA4. ESTIMATE, ssGSEA, CIBERSORT, TIDE and CellMiner algorithms were employed to determine the association of PLEKHA4 with TME, immunotherapy response and drug sensitivities. Immunohistochemistry (IHC)-based tissue microarrays and M2 macrophage infiltration assay were conducted to verify their associations.Results: PLEKHA4 expression was found to be dramatically upregulated and strongly associated with unfavorable overall survival (OS) and disease-specific survival (DSS) in LGG patients, as well as their poor clinicopathological characteristics. Cox regression analysis identified that PLEKHA4 was an independent prognostic factor. Methylation analysis revealed that DNA methylation correlates with PLEKHA4 expression and indicates a better outcome in LGG. Moreover, PLEKHA4 was remarkably correlated with immune responses and TME remodeling, as evidenced by its positive correlation with particular immune marker subsets and the putative infiltration of immune cells. Surprisingly, the proportion of M2 macrophages in TME was strikingly higher than others, inferring that PLEKHA4 may regulate the infiltration and polarization of M2 macrophages. Evidence provided by IHC-based tissue microarrays and M2 macrophage infiltration assay further validated our findings. Moreover, PLEKHA4 expression was found to be significantly correlated with chemokines, interleukins, and their receptors, further supporting the critical role of PLEKHA4 in reshaping the TME. Additionally, we found that PLEKHA4 expression was closely associated with drug sensitivities and immunotherapy responses, indicating that PLEKHA4 expression also had potential clinical significance in guiding immunotherapy and chemotherapy in LGG.Conclusion: PLEKHA4 plays a pivotal role in reshaping the TME of LGG patients, and may serve as a potential predictor for LGG prognosis and therapy.
- 19 June 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1867 (9) , 130411
RNA polymerase I subunit RPA43 activates rRNA expression and cell proliferation but inhibits cell migration
- 19 June 2023
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1867 (9) , 130411
RNA polymerase I subunit RPA43 activates rRNA expression and cell proliferation but inhibits cell migration
- Open Access
- 25 January 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , 102945
Transcription factor AP-2α activates RNA polymerase III–directed transcription and tumor cell proliferation by controlling expression of c-MYC and p53
- 25 January 2023
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 299 (3) , 102945
Open AccessTranscription factor AP-2α activates RNA polymerase III–directed transcription and tumor cell proliferation by controlling expression of c-MYC and p53
- Open Access
- 19 January 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
STAT3 promotes RNA polymerase III-directed transcription by controlling the miR-106a-5p/TP73 axis
Deregulation of Pol III products causes a range of diseases, including neural diseases and cancers. However, the factors and mechanisms that modulate Pol III-directed transcription remain to be found, although massive advances have been achieved. Here, we show that STAT3 positively regulates the activities of Pol III-dependent transcription and cancer cell growth. RNA-seq analysis revealed that STAT3 inhibits the expression of TP73, a member of the p53 family. We found that TP73 is not only required for the regulation of Pol III-directed transcription mediated by STAT3 but also independently suppresses the synthesis of Pol III products. Mechanistically, TP73 can disrupt the assembly of TFIIIB subunits and inhibit their occupancies at Pol III target loci by interacting with TFIIIB subunit TBP. MiR-106a-5p can activate Pol III-directed transcription by targeting the TP73 mRNA 3’ UTR to reduce TP 73 expression. We show that STAT3 activates the expression of miR-106a-5p by binding to the miRNA promoter, indicating that the miR-106a-5p links STAT3 with TP73 to regulate Pol III-directed transcription. Collectively, these findings indicate that STAT3 functions as a positive regulator in Pol III-directed transcription by controlling the miR-106a-5p/TP73 axis.
- 19 January 2023
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 12
Open AccessSTAT3 promotes RNA polymerase III-directed transcription by controlling the miR-106a-5p/TP73 axis
Deregulation of Pol III products causes a range of diseases, including neural diseases and cancers. However, the factors and mechanisms that modulate Pol III-directed transcription remain to be found, although massive advances have been achieved. Here, we show that STAT3 positively regulates the activities of Pol III-dependent transcription and cancer cell growth. RNA-seq analysis revealed that STAT3 inhibits the expression of TP73, a member of the p53 family. We found that TP73 is not only required for the regulation of Pol III-directed transcription mediated by STAT3 but also independently suppresses the synthesis of Pol III products. Mechanistically, TP73 can disrupt the assembly of TFIIIB subunits and inhibit their occupancies at Pol III target loci by interacting with TFIIIB subunit TBP. MiR-106a-5p can activate Pol III-directed transcription by targeting the TP73 mRNA 3’ UTR to reduce TP 73 expression. We show that STAT3 activates the expression of miR-106a-5p by binding to the miRNA promoter, indicating that the miR-106a-5p links STAT3 with TP73 to regulate Pol III-directed transcription. Collectively, these findings indicate that STAT3 functions as a positive regulator in Pol III-directed transcription by controlling the miR-106a-5p/TP73 axis.